Potential therapeutic agents that raise high-density lipoprotein cholesterol levels

Bibliography

• GORDON D, RIFKIND BM: High density lipoprotein as a protective factor against coronary heart disease. N Engl. I Med. (1989) 321:1311–1315.
   PubMed Web of Science ®Google Scholar
• CASTELLI WP, GARRISON RJ, WILSON PW et al: Incidence of coronary heart disease and lipoprotein-cholesterol levels: the Framingham study. JAMA (1986) 256:2835–2838.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• VON ECKARDSTEIN A, NOFER J-R, ASSMANN G: High density lipoproteins and arteriosclerosis. Arteriosclec Thromb. Vasc. Biol. (2001) 21:13–27.
   PubMed Web of Science ®Google Scholar
• SHAH PK, KAUL S, NILSSON J et a/.: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins. Circulation (2001) 104:2498–2502.
   Google Scholar
• FRANCESCHINI G, SIRTORI CR, CADURSO A et al.: Al Milano apoprotein: decreased high density lipoprotein levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. (1980) 66:892–900.
   PubMed Web of Science ®Google Scholar
• PEREZ-MENDEZ O, BRUCKERT E, FRANCESCHINI G et al.: Metabolism of apolipoprotiens Al and All in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis (2000) 148:317–326.
   PubMedGoogle Scholar
• BORTNICK AE, ROTHBLAT GH, STOUDT G et al.: The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J. Biol. Chem. (2000) 275:28634–28640.
   PubMed Web of Science ®Google Scholar
• RUSTS, ROSIER M, FUNKE H et al.: Tangier disease is caused by mutations in the gene encodingATP-binding cassette transporter 1. Nature Gen. (1999) 22:352–355.
   PubMedGoogle Scholar
• BOJANOVSKI D, GREGG RE, ZECH LA et al.: In vivo metabolism of proapolipoprotein A-1 in Tangier disease.' Cl/n. Laval-. (1987) 80:1742–1747.
   Google Scholar
• CHRISTIANSEN-WEBER TA, VOLAND JR, WU Yet al.: Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency. Am. J. Path. (2000) 157:1017–1029.
   Google Scholar
• JOYCE CW, AMAR MJA, LAMBERT G et al.: The ATP binding cassette transporter Al (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. live. Natl. Acad. Sci. USA (2002) 99:407–412.
   PubMedGoogle Scholar
• SINGARAJA RR, FIEVET C, CASTRO G et al.: Increased ABCA1 activity protects against atherosclerosis. " Clin. Invest. (2002) 110:35–42.
   Google Scholar
• SANTAMARINA-FOJO S, REMALEY AT, NEUFELD EB et al: Regulation and intracellular trafficking of the ABCA1 transporter.' Lipid Res. (2001) 42:1339–1345.
   PubMed Web of Science ®Google Scholar
• GERVOIS E PINEDA TORRA I, FRUCHART J-C et al: Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med (2000) 38:3–11.
   PubMedGoogle Scholar
• NEVE BP, FRUCHART J-C, STAELS B: Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharm. (2000) 60:1245–1250.
   PubMedGoogle Scholar
• REPA JJ, TURLEY SD, LOBACCARO J-M A et al.: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289:1524–1529.
   Google Scholar
• DURIEZ P Current practice in the treatment of hyperlipidaemias. Expert Opin. Pharmacother. (2001) 2:1777–1794.
   PubMedGoogle Scholar
• CHINETTI G, LESTAVEL S, BOCHER V et al.: PPAR-a and PPAR-y activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. (2001) 7:53–58.
   PubMed Web of Science ®Google Scholar
• OKAMOTO H, YONEMORI F, WAKITANI K et al.: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406:203–207.
   PubMed Web of Science ®Google Scholar
• TALL AR. Plasma cholesteryl ester transferprotein.j Lipid Res. (1993) 34:1255–1274.
   PubMed Web of Science ®Google Scholar
• INAZU A, KOIZUMI J, MABUCHI H. Cholesteryl ester transfer protein and atherosclerosis. Current Opin. Lipid (2000) 11:389–396.
   Google Scholar
• ZHONG S, SHARP DS, GROVE JS et al:Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels." Clin. Invest. (1996) 97:2917–2923.
   PubMed Web of Science ®Google Scholar
• INAZU A, BROWN ML, HESLER CB et al.: Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl. I Med. (1990) 323:1234–1238.
   PubMed Web of Science ®Google Scholar
• MORIYAMA Y, OKAMURA T, INAZU A et al.: A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prey Med. (1998) 27:659–667.
   PubMed Web of Science ®Google Scholar
• ACTON S, RIGOTTI A, LANDSCHULZ KT et al.: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (1996) 271:518–520.
   PubMed Web of Science ®Google Scholar
• TRIGATTI B, RIGOTTI A, KRIEGER M: The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Carr. Opin. Lipidol (2000) 11:123–131.
   PubMedGoogle Scholar
• TEMEL RE, TRIGATTI B, DEMATTOS RB et al.: Scavenger receptor class B, Type I (SR-BI) is the major route for the delivery of high density lipoprotein cholesterol to the steroidogenic pathway in cultured mouse adrenocortical cells. Proc. Natl. Acad. Sci. USA (1997) 94:13600–13605.
   PubMed Web of Science ®Google Scholar
• LANDSCHULZ KT, PATHAK RK, RIGOTTI A et al.: Regulation of scavenger receptor, class B, Type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J. Clin. Invest (1996) 98:984–995.
   PubMed Web of Science ®Google Scholar
• JIAN B, DE LA LLERA-MOYA M, JI Y et al.: Scavenger receptor class BType I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. " Biol. Chem. (1998) 273:5599–5606.
   Google Scholar
• JI Y, JIAN B, WANG N et al: Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J. Biol. Chem. (1997) 272:20982–20985.
   PubMed Web of Science ®Google Scholar
• GU W, KOZARSKY K, KREIGER M: Scavenger receptor class B,Type 1-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J. Biol. Chem. (2000) 275:29993–30001.
   PubMedGoogle Scholar
• RODRIGUEZ A, WEE S-B: The HDL receptor protein, SR-BI/CLA-1, does not mediate cholesterol efflux from human macrophage foam cells. Circ. Sapp]. (1999) 100:1538.
   Google Scholar
• KOZARSKY KF, DONAHEE MH, GLICK JM et aL: Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thr0177/1. V3SC. (2000) 20:721–727.
   PubMed Web of Science ®Google Scholar
• UEDA Y, ROYER L, GONG E et al.: Lowerplasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B Type I transgenic mice. Biol. Chem. (1999) 274:7165–7171.
   Google Scholar
• RODRIGUEZ A, KERN D, BLACKMAN-M. Principles of Ambulatory Medicine (6th edition). Disorders of Lipoprotein Metabolism Barton, Burton, Zieve (Eds), Lippincott Williams & Wilkins, Philadelphia PA (2003).
   Google Scholar
• BODEN WE, PEARSON TA: Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am. J. Cardiol (2000) 85:645–650.
   PubMed Web of Science ®Google Scholar
• EINHORN D, RENDELL M, ROSENZWEIG J et al: Pioglitazone hydrochloride in combination with metformin in the treatment of Type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin. Ther (2000) 22:1395–1409.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl." Med. (1999) 341:410–418.
   Google Scholar
• MANNINEN V, ELO O, FRICK M et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. "AMA (1988) 260:641–651.
   PubMed Web of Science ®Google Scholar
• DE GROOTH GJ, KUIVENHOVEN JA, STALENHOF et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. Circulation (2002) 105:2159–2165.
   PubMed Web of Science ®Google Scholar